Nassar et al. performed an international multicenter real-world retrospective analysis of 136 patients with unresectable Stage III EGFR-mutated NSCLC who received CRT followed by treatment with osimertinib, durvalumab, or observation [47]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.